CRISPR/Cas9 targeted gene editing and cellular engineering in fanconi anemia

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


The ability to rationally target disease-causing mutations has been made possible with programmable nucleases with the clustered, regularly interspaced short palindromic repeats/Cas9 system representing a facile platform for individualized gene-based medicine. In this study we employed footprint-free reprogramming of fibroblasts from a patient with mutations to the Fanconi anemia I (FANCI) gene to generate induced pluripotent stem cells (iPSCs). This process was accomplished without gene complementation and the resultant iPSCs were able to be gene corrected in a robust manner using the Cas9 nickase. The self-renewing iPSCs that were maintained under feeder-free conditions were differentiated into cells with characteristics of definitive hematopoiesis. This defined and highly efficient procedure employed small molecule modulation of the hematopoietic differentiation pathway and a vascular induction technique to generate hematopoietic progenitors. In sum, our results demonstrate the ability to induce patient-derived FA cells to pluripotency for patient-specific therapeutic cell derivation.

Original languageEnglish (US)
Pages (from-to)1591-1603
Number of pages13
JournalStem Cells and Development
Issue number20
StatePublished - Oct 15 2016

Bibliographical note

Publisher Copyright:
© Copyright 2016, Mary Ann Liebert, Inc. 2016.


Dive into the research topics of 'CRISPR/Cas9 targeted gene editing and cellular engineering in fanconi anemia'. Together they form a unique fingerprint.

Cite this